
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at a new drug called ibrutinib to treat chronic lymphocytic leukaemia (CLL).
If you have been diagnosed with chronic lymphocytic leukaemia (CLL) but don’t have symptoms you may not need to have any treatment. If you do have symptoms, you may have treatment such as chemotherapy. But researchers are looking for new ways to treat CLL.
Ibrutinib is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
We know from research that ibrutinib can help people with CLL. But the researchers need to know more about how it works.
The main aims of this study are to find out
There are 2 groups in this study. You can join the 1st group if you have not yet had treatment for CLL. You can join the 2nd group if your CLL continued to get worse during treatment or came back after treatment.
All of the following must also apply. You
You cannot join this study if any of these apply
People in group 2 cannot join this study if they have already had ibrutinib.
This is a feasibility study. The researchers need 40 people to join. Everyone taking part will have ibrutinib.
Ibrutinib is a capsule. You start by taking 3 capsules once a day. Your doctor will tell you if your dose needs to change. You take the capsules with a glass of water ½ hour before food or 2 hours after food.
You continue taking ibrutinib as long as it is helping you and the side effects aren’t too bad.
The researchers will take some extra blood samples from you. You will also have up to 6 bone marrow tests. They will use these to better understand how ibrutinib works. You must agree to these tests to take part in this study.
You see the doctor to have some tests before taking part in this study. These tests include
During treatment you see the doctor for blood tests and a physical examination
You have 2 or 3 more CT scans during treatment as part of this study.
Ibrutinib is a new drug and there may be side effects we don’t know about yet. The most common side effects reported so far include
Your doctor will talk to you about the possible side effects before you agree to take part in this study.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Hillmen
Bloodwise
NIHR Clinical Research Network: Cancer
Pharmacyclics
University of Birmingham
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”